Carvedilol and cardiac biomarkers in dialysis patients: Secondary analysis of a randomized controlled trial

Grants

Funding Acknowledgements

[ "The BLOCADE Feasibility Study was supported by a Don & Lorraine Jacquot Collaborative Research Initiative Grant (2008), a New Zealand Health Research Council Feasibility Study Grant (10-163), and a National Health and Medical Research Council (NHMRC) Project Grant (1006171). Roche Products, Pty Limited provided Dilatrend (R) at a discounted price. Funding from a Pfizer CVL (2008) grant funded the assays for the biomarkers. Assay materials for galectin-3, hs-TnI and BNP were provided by Abbott Laboratories. Dr Roberts was supported by a NHMRC Training Fellowship (628902). Trial Steering Committee: Matthew A Roberts (Chair), Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, Australia; Alan Cass, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia; Amit X Garg, Division of Nephrology, Department of Medicine, Western University, London, Canada; Carmel M Hawley, Australasian Kidney Trials Network, The University of Queensland, Brisbane; Francesco L Ierino, Department of Nephrology, Austin Health, Melbourne, Australia; Nicole M Isbel, Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia; Henry Krum, Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia; Elaine M Pascoe, Australasian Kidney Trials Network, The University of Queensland, Brisbane, Australia; Vlado Perkovic, The George Institute for Global Health, Sydney, Australia; Helen L Pilmore, Department of Renal Medicine, Auckland City Hospital, Auckland, New Zealand; Andrew M Tonkin, Cardiovascular Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia; Liza A Vergara, Australasian Kidney Trials Network, The University of Queensland, Brisbane, Australia Data Safety Monitoring Board: Adeera Levin (Chair), Department of Medicine, University of British Columbia, Vancouver, Canada; David Hare, Cardiology Department, Austin Health, University of Melbourne, Melbourne, Australia; Andrew Martin, NHMRC Clinical Trials Centre University of Sydney, Sydney, Australia; David C Wheeler, Centre for Nephrology, Division of Medicine, University College London, United Kingdom.", "Endpoint Adjudication Committee: Gregory Fulcher (Chair), Royal North Shore Hospital, Sydney, Australia; Helen Brown, Princess Alexandra Hospital, Brisbane, Australia; David Colquhoun, Wesley Medical Centre, Brisbane, Australia; Dariusz Korczyk, Princess Alexandra Hospital, Brisbane, Australia; Amanda Mather, Royal North Shore Hospital, Sydney, Australia; Andrew Wong, Royal Brisbane and Women's Hospital, Brisbane, Australia Investigators (Site Investigators): Australian sites: Austin Health (Matthew Roberts, Francesco Ierino, Pascal Bisscheroux), John Hunter Hospital (Alastair Gillies, Leanne Garvey), Logan Hospital (Ken-Soon Tan, Erica Lennan), Princess Alexandra Hospital (Nicole Isbel, Markus Pitkin, Karin Ahearn), Royal Adelaide Hospital (Robert P Carroll, Eileen Scott), Royal North Shore Hospital (Bruce Cooper, Jacqueline Pearse), Royal Prince Alfred Hospital (Paul Snelling, Jenny Burman, Samantha Hand), Royal Melbourne Hospital (Eugenie Pedagogos, Connie Karschimkus); New Zealand sites: Auckland City Hospital (Helen Pilmore, Andrew Pilmore); Dunedin Hospital (Robert Walker, Gaye Ellis), Middlemore Hospital (Mark R Marshall, Cecilia Paul) Project Management Team: Australasian Kidney Trials Network, Brisbane, Queensland, Australia: Carmel M Hawley (Chair, AKTN Operations Secretariat), David Johnson (Deputy Chair, AKTN Operations Secretariat), Sunil Badve, Alan Cass, Darsy Darssan, Jean Helyar, Alicia Morrish, Elaine M Pascoe, Peta-Anne Paul-Brent, Donna Reidlinger, Anish Scaria, Liza A Vergara and Lei Zhang." ]